Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
Background and Aims Vedolizumab, a humanised monoclonal antibody for the treatment of inflammatory bowel disease, selectively blocks gut lymphocyte trafficking. This may reduce the risk of respiratory tract infections [RTIs] compared with systemic immunosuppressive therapies. To assess this possibility, we evaluated the rates of RTIs in clinical trials of vedolizumab. Methods Patient-level data from Phase 3 randomised controlled trials [RCTs] of vedolizumab ... Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Oxford University Press Publisher's website
- Journal of Crohn's and Colitis Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- Feagan et al.
- Copyright date:
Copyright © 2018 The Authors. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.